Improving effector activity of antigen specific T cells is a major goal in cancer immunotherapy. Despite the identification of several effector T cell (T EFF )-driving transcription factors (TF), the transcriptional coordination of T EFF biology remains poorly understood. We developed an in vivo T cell CRISPR screening platform and identified a novel mechanism restraining T EFF biology through the ETS family TF, Fli1. Genetic deletion of Fli1 enhanced T EFF responses without compromising memory or exhaustion precursors. Fli1 restrained T EFF lineage differentiation by binding to cis-regulatory elements of effector-associated genes. Loss of Fli1 increased chromatin accessibility at ETS:RUNX motifs allowing more efficient Runx3-driven T EFF biology. CD8 T cells lacking Fli1 provided substantially better protection against multiple infections and tumors. These data indicate that Fli1 safeguards the developing CD8 T cell transcriptional landscape from excessive ETS:RUNX-driven T EFF cell differentiation. Moreover, genetic deletion of Fli1 improves T EFF differentiation and protective immunity in infections and cancer. Utzschneider et al., 2016; Wu et al., 2016; Zhou et al., 2010) TCF-1 represses (directly or indirectly) T EFF -driving TF such as T-bet and Blimp-1(Tiemessen et al., 2014), and may also have a role in enabling epigenetic changes (Xing et al., 2016). Moreover, a second HMG TF, Tox, is essential for the development of the T EX cell fate by promoting T EX differentiation and repressing of the T EFF lineage differentiation(Alfei et al., 2019; Khan et al., 2019; Scott et al., 2019; Seo et al., 2019; Yao et al., 2019). Tox reprograms the open chromatin landscape, inducing global T EX -specific epigenetic changes and repressing chromatin accessibility associated with T EFF differentiation, in part by recruiting epigenetic modifiers including the lysine acetyltransferase Kat7 (Khan et al., 2019). Despite this work, mechanisms that safeguard against commitment to T EFF differentiation remain poorly understood. Such information could be of considerable utility for immunotherapies focused on enhancing anti-tumor or antiviral activity. However, whereas inactivating pathways like TCF-1 or Tox that would de-repress the entire program of T EFF differentiation are of interest, such approaches result in terminal T EFF and may have limited therapeutic benefit because such cells cannot sustain durable responses. Thus, the discovery of mechanisms that selectively de-repress key aspects of T EFF differentiation, particularly those involved in control of numerical expansion and/or protective immunity would be of considerable interest.Here, we used in vivo CRISPR-Cas9 screening in antigen-specific CD8 T cells responding to acute or chronic viral infection to identify key regulators of T EFF and T EX . In particular, we were interested in identifying genes that resulted by gain-of-function, improving T EFF differentiation (i.e. an "Up" screen (Kaelin, 2017)). The CRISPR-Cas9 system has been used to interrogate the cancer-imm...